FindTrial
Sign In

Pelcitoclax

DRUG3 trials

Sponsors

Ascentage Pharma Group Inc., National Cancer Institute (NCI), M.D. Anderson Cancer Center

Conditions

Advanced Endometrial CarcinomaFLAG ChemotherapyLisaftoclaxLymphoblastic Leukemia AcuteMetastatic Endometrial CarcinomaMetastatic Fallopian Tube CarcinomaMetastatic Platinum-Resistant Ovarian CarcinomaMetastatic Primary Peritoneal Carcinoma

Phase 1

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
TerminatedNCT04893759
Ascentage Pharma Group Inc.Neuroendocrine Tumors
Start: 2022-01-06End: 2022-09-14Updated: 2025-04-17
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Active, not recruitingNCT05691504
National Cancer Institute (NCI)Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma +8
Start: 2023-09-14End: 2027-02-01Target: 42Updated: 2026-05-13
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
WithdrawnNCT07428486
M.D. Anderson Cancer CenterFLAG Chemotherapy, Lisaftoclax, Lymphoblastic Leukemia Acute +3
Start: 2026-04-27End: 2026-04-27Updated: 2026-05-07

Related Papers

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Clinical Cancer Research2024-03-0830 citations